Financial Performance - For the year ended December 31, 2025, the revenue was RMB 3,417,355,000, an increase of approximately 15.2% compared to RMB 2,967,235,000 for the year ended December 31, 2024[4] - The profit attributable to equity shareholders for the year ended December 31, 2025, was RMB 1,078,067,000, representing an increase of approximately 18.4% from RMB 910,458,000 for the year ended December 31, 2024[4] - Basic and diluted earnings per share for the year ended December 31, 2025, were approximately RMB 1.27 and RMB 1.26, respectively, reflecting increases of about 14.4% and 15.6% from RMB 1.11 and RMB 1.09 for the year ended December 31, 2024[4] - The total comprehensive income for the year ended December 31, 2025, was RMB 1,089,750,000, compared to RMB 917,551,000 for the year ended December 31, 2024[6] - The operating profit for the year ended December 31, 2025, was RMB 1,202,379,000, compared to RMB 1,045,060,000 for the year ended December 31, 2024[5] - Pre-tax profit for 2025 was RMB 1,196,422,000, an increase from RMB 1,020,106,000 in 2024, representing a growth of approximately 17.3%[34] - The gross profit for 2025 was RMB 2,667,120,000, an increase of about 19.0% from RMB 2,242,102,000 in 2024, with a gross margin of approximately 78.0%, up 2.4 percentage points from 75.6%[79] Assets and Liabilities - The total assets less current liabilities as of December 31, 2025, amounted to RMB 4,979,706,000, an increase from RMB 4,482,282,000 as of December 31, 2024[8] - The net asset value as of December 31, 2025, was RMB 4,837,870,000, compared to RMB 4,393,052,000 as of December 31, 2024[8] - The total assets for reportable segments rose to RMB 6,296,016,000 in 2025, compared to RMB 5,851,628,000 in 2024, marking an increase of 7.6%[22] - The total bank loans amounted to RMB 200,000,000, a decrease from RMB 253,340,000 in 2024[63] - The total lease liabilities as of December 31, 2025, were RMB 12,920,000, compared to RMB 13,829,000 in 2024[64] Dividends - The company proposed a final dividend of HKD 0.40 per share for the year ended December 31, 2025[4] - The interim dividend per share for ordinary shares is HKD 0.33 for 2025, an increase from HKD 0.30 in 2024, totaling RMB 253,308,000, compared to RMB 229,827,000 in 2024[38] - The proposed final dividend per share for ordinary shares is HKD 0.40 for 2025, up from HKD 0.30 in 2024, amounting to RMB 296,201,000, compared to RMB 235,954,000 in 2024[38] Costs and Expenses - The financing costs for the year ended December 31, 2025, were RMB 4,360,000, significantly reduced from RMB 24,888,000 for the year ended December 31, 2024[5] - Employee costs rose to RMB 678,611,000 in 2025 from RMB 593,172,000 in 2024, reflecting an increase of about 14.4%[4] - Administrative expenses increased by approximately 42.9% to RMB 445,631,000 in 2025, up from RMB 311,873,000 in 2024, mainly due to organizational restructuring and increased R&D expenses[82] - Distribution costs rose by approximately 9.3% to RMB 1,072,775,000 in 2025, compared to RMB 981,576,000 in 2024, with the growth rate significantly lower than revenue growth[81] Research and Development - Research and development costs for 2025 amounted to RMB 151,844,000, up from RMB 97,541,000 in 2024, indicating a significant increase of approximately 55.6%[29] - The group made significant progress in R&D, with SK-08 and SK-09 receiving IND approval from the FDA, marking a breakthrough in global drug development[70] - The group launched a multi-modal AIDD platform to optimize drug design and reduce development costs, enhancing R&D efficiency[70] - The establishment of an international scientific advisory board aims to enhance the development of new drugs for chronic kidney disease, with Dr. Jonathan Barratt as the first advisor[71] Inventory and Receivables - The company reported a decrease in inventory to RMB 271,405,000 as of December 31, 2025, from RMB 289,677,000 as of December 31, 2024[7] - Trade receivables, net of impairment, increased to RMB 251,321,000 in 2025 from RMB 234,186,000 in 2024[56] - As of December 31, 2025, inventory balance was RMB 271,405,000, a decrease of approximately 6.3% compared to RMB 289,677,000 on December 31, 2024, with inventory turnover days reduced by 28.8 days to 136.5 days[87] Corporate Governance and Compliance - The company has maintained compliance with relevant laws and regulations without any significant violations for the year ending December 31, 2025[109] - The audit committee, composed of three independent non-executive directors, has reviewed the financial controls and risk management systems to ensure effective oversight[115] - The company has adopted corporate governance principles and standards, aiming for continuous improvement in compliance efficiency and effectiveness[111] - The roles of the chairman and CEO have been clearly delineated to enhance independence and ensure a balance of power and authority[112] Market and Industry Trends - The company experienced a significant shift in the pharmaceutical industry towards value creation rather than scale expansion due to regulatory changes[66] - The overall growth rate of the industry is slowing, but structural opportunities remain for innovative and irreplaceable products and services[66] - The company has been closely monitoring recent developments in national policies affecting the pharmaceutical industry, which are considered major uncertainties[107] Cash Flow and Financing - Net cash generated from operating activities for 2025 was RMB 1,211,796,000, an increase of approximately 11.5% from RMB 1,086,987,000 in 2024[90] - Cash and bank balances, including financial products, increased by approximately 13.4% to RMB 4,383,691,000 as of December 31, 2025[91] - The capital debt ratio decreased by 1.8 percentage points to 4.4% as of December 31, 2025, due to a reduction in net bank loans and an increase in equity attributable to shareholders[94] Shareholder Information - The board proposed a final dividend of HKD 0.4 per share for the year ending December 31, 2025, subject to shareholder approval at the annual general meeting on May 26, 2026[121] - The final dividend, if approved, is expected to be paid on or around June 22, 2026, to shareholders listed on the register as of June 10, 2026[121] - Shareholders must submit completed share transfer documents by 4:30 PM on May 19, 2026, to be eligible to attend and vote at the annual general meeting[122]

Revenue and Profitability - The company's revenue for the interim period of fiscal year 2026 was approximately HKD 342.4 million, an increase of about HKD 26.6 million or 8.4% compared to the same period in fiscal year 2025[9]. - Revenue from primary care services increased by approximately HKD 7.3 million or 3.5% to about HKD 213.9 million, driven by an increase in patient visits[10]. - Revenue from dental services surged by approximately HKD 18.9 million or 67.5% to about HKD 46.8 million, primarily due to increased patient visits and the acquisition of Youde Dental Clinic[10]. - The group's profit for the interim period of FY2026 increased by approximately HKD 2.1 million or 12.3% to about HKD 18.9 million compared to FY2025[22]. - The net profit attributable to the company's owners for the interim period of FY2026 was approximately HKD 18.3 million, an increase of about HKD 1.5 million or 8.5% from FY2025[23]. - The group maintained a net profit margin of approximately 5.5% in FY2026 interim period[22]. - The group reported a net profit of HKD 18,898,000 for the period, compared to HKD 16,822,000 in the previous year, representing an increase of 12.3%[115]. Costs and Expenses - The cost of services provided rose by approximately HKD 15.8 million or 9.5% to about HKD 182.9 million, mainly due to increases in doctor and dentist fees and medical supplies costs[11]. - Administrative expenses rose by approximately HKD 6.3 million or 4.9% to about HKD 135.2 million, primarily due to increased employee-related expenses[18]. - Total costs of services provided amounted to HKD 182,881,000, an increase from HKD 167,070,000, primarily driven by higher costs for medical supplies and doctor fees[119]. Operational Developments - The group is actively participating in public health programs, enhancing community health services through collaborations with the Hong Kong government[27]. - The group is focusing on expanding telemedicine services and preventive health initiatives, including weight management programs and metabolic health screenings[26]. - The group is enhancing its integrated healthcare platform, H2, by expanding preventive medical services and personalized treatment plans[31]. - The group aims to strengthen its operational coordination and digital integration in the dental segment to establish long-term synergies[29]. - The group enhanced its diagnostic services by strengthening health education and customer interaction, including daily health consultations and a series of educational seminars on lifestyle management and disease prevention[32]. - The H2 community pharmacy offers various services, including pharmacist consultations, customized medication, and health screening services, aiming to optimize patient choices and experiences[32]. Workforce and Employment - As of December 31, 2025, the group had 408 full-time employees and 272 part-time employees, an increase from 388 full-time and 377 part-time employees as of December 31, 2024[69]. - The company has a diverse and skilled healthcare team of 464 members, including general practitioners, specialists, and various healthcare professionals, ensuring comprehensive and patient-centered care[46]. Financial Position - The net current assets as of December 31, 2025, were approximately HKD 414.7 million, an increase from HKD 383.9 million as of June 30, 2025[56]. - The company’s interest-bearing bank borrowings were approximately HKD 16.1 million as of December 31, 2025, with a capital debt ratio of about 2.0%[57]. - The company has approximately HKD 100.0 million in undrawn loan facilities as of December 31, 2025, maintaining financial flexibility[57]. - The company’s total assets as of December 31, 2025, were HKD 1,468,963,000, a decrease from HKD 1,471,571,000 as of June 30, 2025[98]. - The company’s cash and cash equivalents increased to HKD 474,531,000 from HKD 439,903,000, showing a growth of 7.8%[97]. Investments and Acquisitions - The company will continue to optimize synergies following the acquisition of Youde Dental, focusing on expanding high-end dental restoration and cosmetic services[50]. - The investment in the limited partnership is recorded at fair value, with a fair value of approximately HKD 61.0 million as of December 31, 2025, representing about 5.8% of the total assets of the group[64]. - The group recorded a fair value loss of approximately HKD 2.2 million related to the investment in the limited partnership[64]. Shareholder Information - The company’s issued share capital remains at HKD 3,796,000, with 379,552,233 shares issued as of both December 31, 2025, and June 30, 2025[141]. - As of December 31, 2025, the company’s major shareholders, including Mr. Chan and Dr. Pang, hold approximately 66.49% of the issued shares through a controlled corporation[84]. Stock Options and Incentives - The company has adopted a stock option plan, with 3,200,000 options granted and 150,000 options unexercised as of December 31, 2025[77]. - The exercise price for the stock options is set at HKD 2.09, with the options exercisable from June 1, 2021, to May 31, 2027[82]. - The total number of stock options and share rewards authorized for grant under the plans is capped at 37,955,223 shares, representing approximately 10% of the issued shares as of the adoption date[81]. Market Outlook - The company maintains a cautiously optimistic outlook for the Hong Kong private healthcare sector, driven by strong demand from an aging population and increasing health awareness[49].

Financial Performance - Revenue for the year ended December 31, 2025, reached RMB 3,446.8 million, an increase of 57.6% compared to RMB 2,187.2 million in 2024[2] - The net loss attributable to shareholders for 2025 was RMB (341.7) million, a decrease of 13.1% from RMB (393.2) million in 2024[2] - The company reported a gross profit of RMB 617.6 million, up from RMB 342.6 million in the previous year[4] - The total comprehensive loss for the year was RMB (216.1) million, an improvement from RMB (485.7) million in 2024[5] - The company reported a loss attributable to shareholders of approximately RMB 342 million for the year ending December 31, 2025, compared to a loss of RMB 393 million for the previous year[11] - The group recorded a loss of approximately RMB 307.3 million for the year ending December 31, 2025, a reduction of about 34.7% from a loss of RMB 470.9 million for the year ending December 31, 2024[61] Assets and Liabilities - Total assets increased by 28.6% to RMB 3,972.0 million in 2025 from RMB 3,087.7 million in 2024[2] - Total liabilities increased to approximately RMB 6,089,189 thousand in 2025 from RMB 4,991,242 thousand in 2024, reflecting a significant rise in financial obligations[7] - Current liabilities exceeded current assets by approximately RMB 2,620 million as of December 31, 2025, compared to RMB 2,479 million in the previous year, indicating ongoing liquidity challenges[11] - The total amount of borrowings and convertible bonds was approximately RMB 3,595 million as of December 31, 2025, up from RMB 3,132 million in 2024[11] - The total equity attributable to shareholders showed a deficit of RMB (2,127.6) million, worsening from RMB (1,877.4) million in 2024[2] Cash Flow and Liquidity - The company has implemented several plans and measures to alleviate cash flow pressure and improve financial conditions, including cash flow forecasts covering at least 12 months from December 31, 2025[13] - The company’s bank balances and cash were approximately RMB 293 million as of December 31, 2025, compared to RMB 147 million in the previous year, indicating a slight improvement in liquidity[11] - The company’s deferred tax liabilities decreased to RMB 16,337 thousand in 2025 from RMB 27,375 thousand in 2024, suggesting a reduction in future tax obligations[7] - The company’s contract liabilities rose significantly to RMB 104,251 thousand in 2025 from RMB 38,968 thousand in 2024, indicating increased customer prepayments or obligations[7] Business Operations and Strategy - The group continues to develop and operate in the automotive parts, education management, and consulting, as well as financial services sectors to generate operational cash flow[14] - The automotive parts business revenue increased to RMB 3,339,089 thousand in 2025 from RMB 2,097,369 thousand in 2024, representing a growth of approximately 59%[22] - Education management and consulting business revenue rose to RMB 62,439 thousand in 2025 from RMB 58,351 thousand in 2024, an increase of about 7%[22] - Financial services business revenue grew to RMB 45,255 thousand in 2025 from RMB 31,496 thousand in 2024, marking a rise of approximately 44%[22] - The company has a diversified strategy focusing on financial services, education management, and automotive parts business[37] Restructuring and Financial Challenges - The company is facing significant uncertainties that may cast doubt on its ability to continue as a going concern, as highlighted by the ongoing financial challenges[12] - The company has appointed a restructuring advisor and a legal advisor to assist in formulating and executing a restructuring plan, with ongoing communication with creditors[14] - The group has successfully obtained court approval to convene a plan meeting and secure creditor approval for restructuring efforts[17] - The group is actively seeking new financing sources to enhance its financial position and support operations[14] - The management acknowledges significant uncertainty regarding the ability to implement the plans and measures, which could impact the company's ability to continue as a going concern[15] Revenue and Profitability Metrics - Total segment revenue reached RMB 3,446,783 thousand in 2025, up from RMB 2,187,216 thousand in 2024, reflecting an overall growth of around 58%[22] - The overall gross profit increased by approximately 80.3% from RMB 342.6 million to RMB 617.6 million for the year ending December 31, 2025[51] - The gross profit margin improved by approximately 2.2 percentage points from 15.7% to 17.9%[52] - The financial services business's revenue increased by approximately 43.8% from RMB 31.5 million to RMB 45.3 million[49] Employee and Operational Costs - Total employee count as of December 31, 2025, is 3,017, an increase from 2,454 employees in 2024[76] - Total compensation and benefits expenses for the year ending December 31, 2025, are approximately RMB 353.0 million, compared to RMB 266.5 million in 2024[76] - Sales and distribution expenses increased by approximately 48.1% to about RMB 122.0 million for the year ending December 31, 2025, compared to RMB 82.4 million for the year ending December 31, 2024[56] - Administrative expenses increased by approximately 15.8% to about RMB 240.8 million for the year ending December 31, 2025, compared to RMB 208.0 million for the year ending December 31, 2024[58] Governance and Compliance - The group adheres to corporate governance codes to enhance its governance standards as of December 31, 2025[80] - The audit committee has reviewed the financial reporting system and internal control effectiveness, and has no objections to the accounting policies adopted by the company[100] - The audit committee has reviewed the auditor's report and agreed with the company's opinion regarding the adequacy and feasibility of the action plan to alleviate liquidity pressure and improve financial conditions[101] Future Outlook - The automotive industry in China is projected to achieve sales of approximately 34.53 million vehicles in 2025, representing a year-on-year growth of about 10.4%[42] - The group is committed to enhancing product quality and customer satisfaction while actively expanding into new markets, particularly in the automotive parts sector[43] - The group plans to leverage its existing brand and technological advantages to develop a new international education service platform[46]

Financial Performance - Everest Medicines achieved a total revenue of RMB 1.707 billion for the year, representing a 142% year-over-year growth[11]. - Revenue for the year ending December 31, 2025, is RMB 1,706.7 million, a significant increase of RMB 1,000.0 million or 141.5% compared to RMB 706.7 million for the year ending December 31, 2024, primarily driven by the sales growth of NAI FUKANG® in commercialized markets[22]. - Adjusted profit for the year ending December 31, 2025, was RMB 187.2 million, a turnaround from a loss of RMB 537.6 million for the year ending December 31, 2024, representing an increase of RMB 724.7 million[23]. - Net loss decreased from RMB 1,041.4 million for the year ending December 31, 2024, to RMB 297.8 million for the year ending December 31, 2025, driven by strong product revenue growth and improved operational efficiency[25]. - The company reported an adjusted profit of RMB 187.2 million for the year ended December 31, 2025, compared to an adjusted loss of RMB 537.6 million for the year ended December 31, 2024[102]. Product Development and Commercialization - The drug Naimu Kang® became the only fully approved treatment for primary IgA nephropathy (IgAN) in China, significantly boosting commercial growth and generating over RMB 1 billion in sales within its first year of inclusion in the national medical insurance catalog[11]. - The approval of 维适平® for treating moderate to severe active ulcerative colitis (UC) in China marks a significant milestone, with plans for extensive physician-patient education and a professional sales team to support its launch[13]. - NEFECON® (Budesonide) is the first drug globally for the targeted treatment of IgA nephropathy, showing a 66% delay in kidney function decline in the Chinese population and extending the time to dialysis or kidney transplant by 12.8 years[27]. - The company plans to launch a Gd-IgA1 diagnostic tool for IgA nephropathy patients this year, providing a non-invasive method for disease diagnosis and monitoring[17]. - The company aims to enhance its commercialization platform and global R&D layout, focusing on expanding its product portfolio and accelerating key assets towards blockbuster status[19]. Research and Development - The mRNA platform has made significant progress, with the personalized mRNA tumor vaccine project EVM16 completing initial dose escalation in a researcher-initiated clinical trial[15]. - EVER001 (希布替尼) has shown positive results in its Phase 1b/2a clinical trial for primary membranous nephropathy (pMN), enhancing the company's presence in the nephrology field[14]. - The company is committed to a dual-driven strategy, focusing on external strategic collaborations and continuous investment in independent R&D, including mRNA technologies[20]. - The company has developed an AI-driven mRNA platform for tumor therapeutic vaccines and autologous CAR-T pipeline, demonstrating efficacy in preclinical models[47]. - The company plans to submit global new drug clinical trial applications for EVM18 in multiple autoimmune disease indications in 2026[49]. Market Expansion and Strategic Partnerships - The company has established a clear five-year development blueprint aimed at becoming a leading platform for the commercialization of innovative drugs in China[10]. - Strategic investments, including becoming the largest shareholder in 新桥生物, are expanding the company's product pipeline into ophthalmology and cardiovascular/metabolic fields[16]. - The company has established a strategic cooperation agreement with Haisen Biotech to provide commercialization services for six approved products in critical care, cardiovascular, and metabolic fields[67]. - The exclusive licensing agreement for MT1013 will strengthen the company's position in the renal and autoimmune disease sectors, expanding its product coverage[73]. - The strategic partnership with Visara, Inc. allows the company to develop and commercialize VIS–101 in Greater China and Southeast Asia, targeting unmet clinical needs in ophthalmology[72]. Financial Health and Investments - Cash and cash equivalents, along with bank deposits, amounted to RMB 2,731.5 million as of December 31, 2025[25]. - The company’s cash and cash equivalents totaled RMB 2,731.5 million as of December 31, 2025, compared to RMB 1,603.3 million as of December 31, 2024[81]. - The company has completed the construction of the Jiaxing production base and initiated a new project for local production of VELSIPITY® in 2025, funded by internal resources and bank financing[113]. - The company has not entered into any hedging transactions to manage potential foreign currency fluctuations as of December 31, 2025[116]. - The company’s investment strategy focuses on low-risk, liquid instruments to generate returns above existing bank deposit rates while emphasizing capital preservation and liquidity[108]. Employee and Shareholder Information - The company employed 812 staff as of December 31, 2025, an increase from 665 in 2024, with 70.08% in commercialization roles[132][133]. - Total employee compensation for the year ending December 31, 2025, amounted to RMB 771.5 million, compared to RMB 586.6 million for the year ending December 31, 2024[135]. - The company has adopted a share plan to incentivize employees, with further details available in the annual report[135]. - Major shareholders include Vistra Trust (Singapore) with 85,222,427 shares, also representing 24.10% of the equity[161]. - The company has various stock option plans in place for its directors, with specific exercise prices and share allocations detailed for each[160].

Financial Performance - Total revenue for the year ended December 31, 2025, was RMB 8,123.4 million, a decrease of 30.5% compared to RMB 11,598.5 million for the year ended December 31, 2024[3]. - The company reported a loss attributable to shareholders of RMB 527.4 million, compared to a loss of RMB 345.9 million in the previous year, representing a 52.4% increase in losses[5]. - Basic loss per share for the year was RMB 0.99, compared to RMB 0.65 in the previous year, indicating a worsening financial performance[6]. - Gross profit margin turned negative at -0.84% for 2025, down from a positive margin of 1.29% in 2024[5]. - Total comprehensive loss for the year was RMB 731.9 million, compared to RMB 469.5 million in 2024, reflecting a 55.8% increase in total losses[6]. - Operating cash flow for the year ended December 31, 2025, was RMB 359,368 thousand, a decrease of 61.9% from RMB 942,525 thousand in 2024[11]. - The company reported a net loss of RMB 527,391 thousand for the year ended December 31, 2025, compared to a net loss of RMB 345,890 thousand in the previous year, representing an increase in losses of approximately 52.5%[9]. - Total comprehensive income for the year ended December 31, 2025, was a loss of RMB 526,849 thousand, compared to a loss of RMB 340,614 thousand in 2024, indicating a deterioration of approximately 54.7%[9]. - The company reported a total loss before tax of RMB 678,819 thousand for the year ended December 31, 2025[96]. - The net loss before tax for the year ended December 31, 2025, was RMB (678,819,000), compared to RMB (538,813,000) for the year ended December 31, 2024, indicating an increase in losses of 26%[105]. Assets and Liabilities - Non-current assets decreased to RMB 7,619.5 million in 2025 from RMB 8,581.0 million in 2024, a decline of 11.2%[7]. - Current liabilities decreased to RMB 4,827.6 million in 2025 from RMB 5,650.2 million in 2024, a reduction of 14.5%[8]. - The company's total equity decreased to RMB 3,582.5 million in 2025 from RMB 4,337.3 million in 2024, a decline of 17.4%[8]. - The company’s total liabilities included a significant offset of RMB 1,616,497,000 against total revenue, indicating a focus on managing internal trade[91]. - The company’s total liabilities increased, with a notable rise in contract liabilities, which increased by RMB 46,527 thousand in 2025[11]. - The company’s total liabilities decreased to RMB 5,000,000,000 in 2025 from RMB 6,000,000,000 in 2024, reflecting a strategic focus on optimizing the capital structure[181]. Cash Flow and Financing - The company reported a financing cost of RMB 154.3 million, an increase from RMB 144.0 million in the previous year, indicating rising financial expenses[5]. - As of December 31, 2025, the net cash used in financing activities was RMB (868,012) thousand, an increase from RMB (633,446) thousand in the previous year[13]. - The company raised bank loans amounting to RMB 2,293,347 thousand in 2025, compared to RMB 1,943,112 thousand in 2024, indicating an 18% increase in financing through bank loans[13]. - Cash and cash equivalents decreased by RMB 259,778 thousand in 2025, a significant improvement compared to a decrease of RMB 413,890 thousand in 2024[13]. - The company paid interest of RMB (137,674) thousand in 2025, a decrease from RMB (161,118) thousand in 2024, representing a 14% reduction in interest expenses[13]. - The company received government subsidies related to assets amounting to RMB 30,619 thousand in 2025, compared to RMB 8,919 thousand in 2024, indicating a significant increase in support[12]. - The company has pledged assets totaling RMB 3,406,700,000 as collateral for financing as of December 31, 2025, compared to RMB 3,167,589,000 in 2024[176]. Inventory and Impairment - Inventory levels decreased significantly to RMB 280.8 million in 2025 from RMB 525.9 million in 2024, a reduction of 46.8%[7]. - The company recognized impairment losses on property, plant, and equipment and intangible assets amounting to RMB 507,914,000 for the year ended December 31, 2025, with no such losses reported in 2024[104]. - The carrying amount of inventory as of December 31, 2025, was RMB 280,810,000, down from RMB 525,940,000 in 2024, showing a decrease of approximately 46.8%[85]. - The company plans to continue evaluating its impairment assessments for property, plant, and equipment, which may affect future financial results[87]. Revenue Breakdown - Total revenue from customer contracts for the year ended December 31, 2025, was RMB 9,739,901,000, with a net revenue of RMB 8,123,404,000 after eliminations[90]. - The revenue breakdown included RMB 4,296,893,000 from coke, RMB 2,808,836,000 from derivative chemicals, and RMB 1,385,082,000 from energy products[90]. - The company reported a significant decrease in coke revenue from RMB 8,059,643,000 in 2024 to RMB 4,292,561,000 in 2025[91]. - The company recognized revenue of RMB 53,689,000 from performance obligations fulfilled during the year, down from RMB 117,226,000 in 2024, indicating a decline of 54.2%[167]. Employee Compensation - The total remuneration for the five highest-paid individuals in the group for the year ending December 31, 2025, was RMB 2,849 thousand, down from RMB 3,167 thousand in 2024[115]. - The total remuneration for executive directors for the year ending December 31, 2024, was RMB 623 thousand for Wang Mingzhong and RMB 393 thousand for Li Tianxi[111]. - The total remuneration for the board of directors and supervisors for the year ending December 31, 2025, was RMB 2,720 thousand[113]. - Total compensation for key management personnel increased to RMB 8,191,000 in 2025 from RMB 7,334,000 in 2024, representing an increase of 11.7%[180]. Tax and Deferred Tax - Deferred tax assets are recognized based on the expected taxable profits, which involve significant management judgment and assumptions that could impact future net profits[89]. - The total deferred tax assets as of December 31, 2025, are RMB 111,730,000, down from RMB 173,994,000 in 2024, indicating a decrease of approximately 35.8%[147]. - The company reported a deferred tax expense of RMB 41,453,000 for the year ended December 31, 2025, compared to a deferred tax benefit of RMB (79,976,000) in 2024[104]. Credit Risk and Management - The group’s credit risk concentration was significantly reduced, with the top five customers accounting for only 17% of trade receivables in 2025, down from 74% in 2024[191]. - The expected credit loss for trade receivables as of December 31, 2025, is RMB 210,581,000, compared to RMB 204,496,000 in 2024, indicating a slight increase[197]. - The group has no significant credit risk concentration in cash equivalents, term deposits, and restricted bank balances, as all deposits are held in reputable banks with high credit ratings[194]. - The group’s internal credit risk assessment includes categories such as low risk, watch list, and doubtful, with no evidence of credit impairment for trade receivables as of December 31, 2025[196]. Lease and Asset Management - The company applies short-term lease recognition exemption for office premises and employee dormitories with lease terms of 12 months or less without purchase options[32]. - Right-of-use assets are measured at cost less any accumulated depreciation and impairment losses, adjusted for any remeasurement of lease liabilities[33]. - Lease liabilities are initially measured at the present value of unpaid lease payments as of the lease commencement date[36]. - The carrying amount of right-of-use assets as of December 31, 2025, was RMB 405,956,000, down from RMB 417,375,000 in 2024[121].

Financial Performance - For the fiscal year ending December 31, 2025, product sales and commercialization rights revenue increased by 90% to RMB 574.1 million (USD 82.1 million) compared to RMB 980.7 million (USD 134.3 million) for the previous year[5][9]. - The company reported a net loss of RMB 1,243.0 million (USD 177.7 million), an increase of 206.4% from RMB 405.7 million (USD 55.6 million) in the previous year[11]. - Total revenue for the year ended December 31, 2025, was RMB 574,120 thousand, a decrease of 41.3% compared to RMB 980,650 thousand in 2024[75]. - Gross profit for 2025 was RMB 525,182 thousand, down from RMB 951,565 thousand in 2024, reflecting a gross margin decline[75]. - The company reported a basic and diluted loss per share of RMB 3.49 for 2025, compared to RMB 1.34 in 2024, indicating worsening profitability[75]. - The net cash outflow from operating activities was RMB 1,174.1 million for the year ending December 31, 2025, compared to RMB 111.4 million for the year ending December 31, 2024[128]. - The net cash inflow from financing activities was RMB 2,540.1 million for the year ending December 31, 2025, compared to RMB 314.8 million for the year ending December 31, 2024[129]. Research and Development - Research and development expenses increased by 20.1% to RMB 1,137.4 million (USD 162.7 million) from RMB 947.2 million (USD 129.8 million) in the previous year[10]. - The company is currently conducting nine ongoing Phase III clinical trials, with four approved by the FDA and EMA[5][7]. - The company has received IND approval for its proprietary BTK-targeted protein degrader APG-3288, preparing to initiate clinical studies for relapsed/refractory hematologic malignancies[15]. - The company is focusing on developing differentiated therapeutic candidates through its internal discovery capabilities, targeting traditionally undruggable proteins[55][56]. - The company is conducting global Phase III registration trials for Lisaftoclax in combination with AZA for frontline HR-MDS patients and with BTK inhibitors for previously treated CLL/SLL patients[160]. Product Sales and Market Expansion - Sales of Nairike® (Aorebatin) grew by 81% year-on-year to RMB 435.3 million (USD 62.2 million) from RMB 241.0 million (USD 33.0 million) in the previous year[5][9]. - The sales revenue of Lisangtuo® (Lazertinib) in China reached RMB 70.6 million (USD 10.1 million) for the year ending December 31, 2025[14]. - The commercialization of Lishengtuo® (Lisatochra) was initiated following its approval for treating adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in July 2025[6][7]. - The increase in sales and distribution expenses by 80.4% to RMB 353.6 million (USD 50.6 million) was attributed to the commercialization activities of Lishengtuo® and Nairike®[9][10]. - The number of hospitals and DTP pharmacies with access to Nairike® (Aurebacitinib) increased by 12.4% to 825 as of December 31, 2025, with the number of hospitals rising approximately 36.5% to 355[14]. Strategic Partnerships and Collaborations - The company has established collaborations with leading biotech and pharmaceutical companies, including AstraZeneca, Merck, and Pfizer, as well as research institutions like Dana-Farber Cancer Institute and Mayo Clinic[22]. - The company continues to collaborate closely with Takeda Pharmaceutical to implement the option agreement for Orelabrutinib, highlighting ongoing strategic partnerships[74]. - The company is strategically seeking partnerships to maximize the potential of its product portfolio and provide sustainable support for pipeline development[161]. Clinical Trials and Approvals - The FDA and EMA approved Lisangtuo® (Lazertinib) for the treatment of adult CLL/SLL patients who have received at least one prior systemic therapy including a BTK inhibitor[14]. - The global registration Phase III trial for Nairike® (Aurebacitinib) in first-line Ph+ ALL patients received FDA and EMA approval[17]. - The ongoing global Phase III clinical trial (GLORA) for Lishangtuo in combination with BTK inhibitors for previously treated CLL/SLL patients has received approvals from FDA, EMA, and CDE[35]. - The company is also conducting a global Phase III registration trial POLARIS-1 for Orebatin in first-line Ph+ ALL patients, with FDA and EMA approval[155]. Financial Position and Liquidity - The company’s cash and bank balances rose by 95.9% to RMB 2,470.1 million (USD 353.2 million) from RMB 1,261.2 million (USD 172.8 million) in the previous year, primarily due to cash inflows from the IPO and subsequent share placements[11]. - The company's equity increased to RMB 1,334,212 thousand in 2025, compared to RMB 274,162 thousand in 2024, showing significant growth in shareholder value[78]. - The current ratio improved to 1.8 for the year ending December 31, 2025, from 1.3 for the year ending December 31, 2024[130]. - The total liabilities as of December 31, 2025, amount to RMB 1,979.7 million, an increase from RMB 1,668.5 million in 2024, indicating a year-over-year growth of approximately 18.6%[139]. Corporate Governance and Compliance - The company has a comprehensive governance structure in place, ensuring compliance with corporate governance codes and maintaining a balance of power within the board[162]. - The company has established an audit committee consisting of two independent non-executive directors and one non-executive director[200]. - The company has not adopted any new accounting standards that would impact its financial reporting, maintaining consistency in its financial practices[80].

Financial Performance - Baiying Holdings Group Limited announced its audited annual performance for the year ending December 31, 2025[2]. - Revenue for the year ended December 31, 2025, is projected to be RMB 45,433 thousand, an increase from RMB 36,027 thousand in 2023, reflecting a growth of approximately 26.7%[15]. - The company reported a net profit of approximately RMB 7,000 thousand for the year ended December 31, 2025, recovering from a net loss of RMB 17,342 thousand in 2024[21]. - Revenue increased from RMB 22.4 million for the year ended December 31, 2024, to RMB 45.4 million for the year ended December 31, 2025, primarily due to a significant increase in financing lease services by RMB 11.5 million and the contribution of new financial information services by RMB 8.2 million[49]. - The company's profit increased significantly from a loss of RMB 17.3 million for the year ending December 31, 2024, to a profit of RMB 7.0 million for the year ending December 31, 2025, primarily due to a substantial increase in revenue[61]. - The net profit margin increased significantly from -77.4% in 2024 to 15.3% in 2025, attributed to a substantial increase in revenue[84]. Business Operations - The company completed the sale of its vinegar business for RMB 135 million in June 2025, allowing it to focus resources on its core financial services[20]. - The company aims to enhance its financial information service capabilities, which began contributing to revenue in March 2025 through a SaaS-based customer relationship management system[20]. - The company is focusing on the financing leasing sector while also ensuring stable operations in the paper industry, aiming for sustainable growth[17]. - The company serves 90 clients across 19 provinces in China, with revenue from financing services and paper products trade increasing from RMB 22.4 million in 2024 to RMB 45.4 million in 2025[21]. - The company aims to expand its financial information services business, leveraging existing financing leasing operations and risk control experience to create a new growth point[92]. - The company will continue to deepen customer cooperation in the paper industry, ensuring stable and healthy business development[92]. Financial Position - The total assets of the company decreased from RMB 318,957 thousand in 2022 to RMB 278,819 thousand in 2023, but are expected to rise to RMB 376,858 thousand by 2024[15]. - The total liabilities decreased from RMB 63,868 thousand in 2022 to RMB 39,889 thousand in 2023, indicating improved financial health[15]. - The company's total liabilities decreased, contributing to an increase in net assets from RMB 221.5 million as of December 31, 2024, to RMB 263.6 million as of December 31, 2025[69]. - Loans and receivables surged from RMB 173.1 million as of December 31, 2024, to RMB 333.5 million as of December 31, 2025, indicating a significant growth in financial transactions[71]. - The company's return on equity improved from -7.8% for the year ended December 31, 2024, to 2.64% for the year ended December 31, 2025[82]. - The debt-to-equity ratio decreased from 0.49 as of December 31, 2024, to 0.22 as of December 31, 2025, indicating reduced leverage[84]. Cash Flow - The net cash used in operating activities for the year ending December 31, 2025, was RMB 126.6 million, influenced by an operating loss of RMB 8.2 million before changes in working capital[65]. - The net cash generated from investing activities for the year ending December 31, 2025, was RMB 73.8 million, mainly from proceeds of RMB 20.3 million from the sale and redemption of investments[66]. - The net cash generated from financing activities for the year ending December 31, 2025, was RMB 67.3 million, which included borrowings of RMB 147.1 million offset by repayments of RMB 76.9 million[67]. Regulatory Compliance - The company emphasizes compliance with GEM listing rules and is committed to sustainable development in its business operations[117]. - The company complied with all major regulatory capital requirements and borrowing restrictions as of December 31, 2025[41]. - The financing lease company’s risk assets did not exceed eight times its net assets, adhering to regulatory standards[44]. - All independent non-executive directors have confirmed their independence according to GEM Listing Rule 5.09[145]. - The company confirmed compliance with the minimum public float requirement of at least 25% as per GEM listing rules[138]. Management and Governance - The board consists of three executive directors, one non-executive director, and three independent non-executive directors as of December 31, 2025[181]. - The company has adopted the corporate governance code and has complied with its provisions during the reporting period[180]. - The audit committee is chaired by an independent non-executive director with relevant financial expertise, ensuring effective oversight of financial reporting[194]. - The company has established three board committees to oversee various aspects of its operations[181]. - The company has taken out appropriate directors and officers liability insurance, effective throughout the year ending December 31, 2025[148]. Risk Management - Credit risk is identified as the most significant inherent risk due to the focus on providing equipment financing solutions to SMEs and individual entrepreneurs[122]. - The company has not faced any liquidity risks that could significantly impact its business, financial condition, or operational performance[123]. - The company maintains a good relationship with employees and customers, with no significant disputes reported[120]. Shareholder Information - The company's public float was 35.36% as of December 31, 2025, with major shareholders holding 50.58%[139]. - The company did not propose any dividend distribution for the year ending December 31, 2025[134]. - The company has not issued or granted any convertible securities, options, or similar rights during the reporting period[141]. Legal Matters - There are currently 13 pending legal cases initiated by the company, which are not expected to have a significant adverse impact on its business or financial condition[159]. - The company has no significant transactions or arrangements involving directors or their related entities during the reporting period[152].

Financial Performance - Total revenue for 2025 reached RMB 31,629,416, an increase of 13.4% compared to RMB 27,984,605 in 2024[10] - Gross profit for 2025 was RMB 27,266,760, reflecting a gross margin of approximately 86.2%[10] - Net profit attributable to shareholders for 2025 was RMB 7,711,055, up 21.8% from RMB 6,336,527 in 2024[10] - The company’s EBITDA for 2025 was RMB 8,879,057, an increase from RMB 7,442,791 in 2024[10] - The proposed final dividend per share for 2025 is RMB 2.0, consistent with the previous year[10] - The company reported a significant loss of -$4.394 billion in the latest quarter, reflecting ongoing challenges in the market[1] - Revenue increased by 13.0% from RMB 27,984.6 million for the year ending December 31, 2024, to RMB 31,629.4 million for the year ending December 31, 2025, primarily due to growth in innovative drug sales and licensing income[92] - Sales cost rose by 13.4% from RMB 3,848.2 million for the year ending December 31, 2024, to RMB 4,362.7 million for the year ending December 31, 2025, driven by increased drug sales[93] - Gross profit increased by 13.0% from RMB 24,136.4 million for the year ending December 31, 2024, to RMB 27,266.8 million for the year ending December 31, 2025, with a stable gross margin of 86.2%[94] - Net profit margin improved from 22.6% for the year ending December 31, 2024, to 24.4% for the year ending December 31, 2025, due to growth in gross profit and improved cost efficiency in selling, general, and administrative expenses[94] Research and Development - R&D expenses for 2025 amounted to RMB 8,723,852, representing a 6% increase from RMB 8,227,838 in 2024[10] - The company has invested significantly in R&D, with expenditures reaching $2,183 million this quarter, reflecting a commitment to innovation[13] - The R&D pipeline includes 15 products under NDA review and 28 products entering Phase III trials, indicating a robust development strategy[32] - The company is committed to enhancing its R&D innovation system and improving efficiency and success rates while managing higher R&D risks due to increasing competition and regulatory standards[85] - The company has established 15 R&D centers globally and initiated the first overseas clinical trials for 5 innovative drug assets during the reporting period[73] - The company is focusing on important pathological targets and pathways related to autoimmune diseases, utilizing various drug modalities including small molecules and monoclonal antibodies[76] Product Pipeline and Innovation - The company has received approval for 24 first-class innovative drugs and 5 second-class new drugs in China, maintaining a leading position in innovation[12] - The company aims to expand its pipeline, which is currently ranked second globally according to Citeline[12] - The pipeline includes multiple products in various clinical stages, with a focus on oncology and infectious diseases, indicating a diverse research strategy[15] - The company is actively pursuing orphan drug designations from the FDA and EMA for several of its candidates, which could provide market exclusivity[13] - The company is advancing multiple drug candidates, including SHR7280 and HRS5580, targeting various conditions such as GNB infections and pain management[13] - The company is focusing on expanding its product pipeline, with several candidates in Phase II and III clinical trials, including treatments for asthma and chronic pain[13] - The company is developing multiple drugs targeting obesity and diabetes, including GLP-1/GIP and insulin-based therapies, with ongoing clinical trials in China[70] Market Expansion and Strategic Partnerships - The company is exploring strategic partnerships and potential acquisitions to enhance its market presence and accelerate product development[13] - The company has established a commercialization network covering over 25,000 hospitals and more than 200,000 offline retail pharmacies across over 30 provincial-level administrative regions in China[55] - The company is focused on accelerating the commercialization of innovative products and expanding overseas licensing partnerships to enhance growth[30] - The company is actively pursuing international markets, with several drugs under review in the US and Europe, indicating potential for global revenue growth[66] - The company has formed partnerships with renowned multinational pharmaceutical companies such as Merck KGaA, MSD, and GSK for overseas business expansion[73] Corporate Governance - The company has established four specialized committees within the board to provide strategic guidance and enhance corporate governance standards[132] - The board believes that high corporate governance standards are crucial for protecting shareholder interests and enhancing corporate value[132] - The company has mechanisms in place to ensure board independence, including a nomination committee with a majority of independent non-executive directors[143] - The company has established a code of conduct for directors' securities transactions, confirming compliance since the listing date until December 31, 2025[135] - The board consists of 11 members, including 6 executive directors, 1 non-executive director, and 4 independent non-executive directors, ensuring a strong independent element for effective decision-making[136] Employee and Diversity Initiatives - The company aims to increase the proportion of female employees to 45% by 2030, with ongoing support for women's career development through initiatives like the Women's Leadership Program[185] - By 2025, the percentage of female employees is projected to reach 45.6%, marking a stable growth of 0.7% from the previous year[183] - A total of 13,800 employees participated in diversity training during the reporting period, accumulating 6,900 hours of training[181] - The company has adopted a policy to eliminate all forms of bias and discrimination, fostering a fair and trustworthy work environment[181] Risk Management - The company has established a comprehensive risk management system to identify, assess, monitor, and mitigate various operational, financial, and legal risks[195] - The internal control policies and guidelines have been implemented to identify internal control deficiencies and conduct internal audits regularly, with oversight from the audit committee[197] - The company’s risk management policies are aligned with the regulations of the Shanghai Stock Exchange and Hong Kong Stock Exchange, covering risk management, related transactions, financial reporting, and information disclosure[199]

Financial Performance - The company reported a revenue of RMB 3.5 million for the year ending December 31, 2025, a significant decrease from RMB 38.4 million in 2024[6]. - The company recorded a net loss of RMB 205.1 million for the year ending December 31, 2025, down from RMB 903.4 million in 2024, reflecting a significant improvement[9]. - Adjusted net loss, excluding share-based compensation expenses, was RMB 198.4 million for 2025 compared to RMB 887.2 million in 2024[11]. - The group reported a total revenue of RMB 3.5 million for 2025, significantly lower than RMB 38.4 million in 2024, resulting in a net loss of RMB 205.1 million compared to a loss of RMB 903.4 million in the previous year[67]. - The company recorded a total comprehensive loss of RMB 168,192,000 in 2025, down from RMB 919,728,000 in 2024, showing a substantial reduction in overall losses[68]. - The group reported a pre-tax loss of RMB 205,092,000 for the year ending December 31, 2025, compared to a loss of RMB 903,428,000 in 2024, indicating a significant reduction in losses[99]. Income and Expenses - Other income and gains decreased from RMB 97.2 million in 2024 to RMB 54.1 million in 2025, primarily due to the absence of certain trade receivables and reduced bank interest income[7]. - Cash and bank balances decreased from RMB 556.5 million in 2024 to RMB 271.4 million in 2025, mainly due to loan repayments and ongoing R&D investments[6]. - Administrative expenses decreased from RMB 75.2 million in 2024 to RMB 66.3 million in 2025, reflecting cost-saving measures and improved operational efficiency[8]. - R&D expenses slightly decreased from RMB 183.4 million in 2024 to RMB 182.3 million in 2025, as the company continues to prioritize its respiratory vaccine candidates[8]. - Sales and distribution expenses decreased from RMB 19.7 million for the year ending December 31, 2024, to RMB 5.1 million for the year ending December 31, 2025, a reduction of RMB 14.6 million[41]. - Other expenses decreased significantly from RMB 738.2 million for the year ending December 31, 2024, to RMB 7.8 million for the year ending December 31, 2025, a reduction of RMB 730.4 million[47]. Research and Development - The company announced positive interim results for its RSV+hMPV±PIV3 vaccine candidates in October 2025, indicating progress in clinical trials[12]. - The company is prioritizing resources to advance its proprietary RSV vaccine candidates to solidify its best-in-class and first-in-class positions in the global RSV and respiratory vaccine markets[20]. - The company plans to initiate Phase I clinical trials for SCB-1019 (RSV), SCB-1022 (RSV + hMPV), and SCB-1033 (RSV + hMPV + PIV3) in early 2025, following the approval of the US IND clinical trial[24]. - Initial results from a Phase I clinical trial involving 144 participants (48 per vaccine group) showed that SCB-1022 and SCB-1033 have potential best-in-class neutralizing antibody responses against RSV, hMPV, and PIV3, with no immune interference against RSV[25]. - The company achieved positive preliminary data on safety, efficacy, and pharmacokinetics in a Phase I clinical trial for SCB-219M, with an Ib phase trial set to start in November 2024[32]. Market Position and Strategy - The company has established a leading position in the global RSV vaccine market with its adjuvant-free RSV vaccine candidates, supported by positive results from international Phase I clinical trials conducted in Australia and the US[19]. - The company continues to focus on strengthening its core capabilities in vaccine development and is actively exploring global collaboration opportunities to maximize the commercial potential of its proprietary RSV vaccine candidates[34]. - The company aims to address unmet needs in severe respiratory infectious diseases through its leading respiratory vaccine product portfolio[23]. Corporate Governance and Compliance - The company is committed to high standards of corporate governance and has adopted the principles and code provisions of the corporate governance code[111]. - The company has adopted the standard code of conduct as per the listing rules, ensuring compliance among all directors during the reporting period[120]. - The board of directors includes both executive and non-executive members, ensuring a diverse governance structure[150]. Legal and Regulatory Matters - The company maintains its emergency use authorization for its COVID-19 vaccine obtained in December 2022[15]. - The group has entered into a settlement agreement with GAVI, agreeing to pay a one-time cash payment of $7 million and deferred cash payments of $1.5 million every six months or a low single-digit percentage of the group's cash balance, whichever is higher[74]. - GAVI has not exercised its purchase option under the amended pre-purchase agreement and has claimed a total of USD 224 million in advance payments, which the company believes lacks factual basis[107]. Future Outlook and Risks - The company faces significant risks including delays in clinical development, regulatory approvals, and commercialization of candidate products, which could severely impact business operations[136]. - The group anticipates having sufficient operating funds to meet financial obligations over the next twelve months, based on cash flow forecasts[75]. - The company cannot guarantee the successful development and commercialization of its candidate drugs and vaccines, urging shareholders and potential investors to act cautiously when trading shares[143].

Financial Performance - Total revenue for the year ended December 31, 2025, reached RMB 31,629.42 million, a 13.4% increase from RMB 27,984.61 million in 2024[8] - Gross profit for the same period was RMB 27,266.76 million, reflecting a gross margin of approximately 86.2%[8] - Net profit attributable to shareholders for 2025 was RMB 7,711.06 million, up 21.8% from RMB 6,336.53 million in 2024[8] - Basic earnings per share for 2025 were RMB 1.19, compared to RMB 1.00 in 2024, marking a 19% increase[8] - The EBITDA for 2025 was reported at RMB 8,879.06 million, showing a growth of 19.4% from RMB 7,442.79 million in 2024[8] - The company reported a significant increase in revenue, with a year-over-year growth of 25% to reach $1.5 billion[11] - The company reported a net loss of $5 million, a decrease from a loss of $10 million in the previous quarter[11] - The company reported a significant loss of -$4,394 million in the latest quarter, reflecting ongoing challenges in the market[1] - Revenue increased by 13.0% from RMB 27,984.6 million for the year ending December 31, 2024, to RMB 31,629.4 million for the year ending December 31, 2025, driven by growth in innovative drug sales and licensing income[90] - Gross profit rose by 13.0% from RMB 24,136.4 million for the year ending December 31, 2024, to RMB 27,266.8 million for the year ending December 31, 2025, with a stable gross margin of 86.2%[92] Research and Development - Research and development expenses increased to RMB 8,723.85 million, representing 27.6% of total revenue[8] - The company has received approval for 7 Class 1 innovative drugs during the reporting period, bringing the total to 24 approved in China[17] - The R&D pipeline includes 15 products under NDA review and 28 products entering Phase III trials, indicating a robust development strategy[30] - The company is focusing on the development of new products, particularly in the oncology sector, with several candidates in late-stage clinical trials[1] - The company is committed to addressing unmet medical needs in chronic diseases, as evidenced by its diverse pipeline[33] - The company is exploring new technologies and drug combinations to enhance treatment efficacy, such as combining therapies for advanced non-small cell lung cancer[35] - The company is advancing multiple drug candidates in various stages of clinical trials, including treatments for small cell lung cancer and advanced liver cancer in China[62] - The company is developing multiple drugs targeting obesity and diabetes, including GLP-1/GIP and insulin-based therapies, with ongoing clinical trials in China[68] - The company has established 15 R&D centers globally and initiated the first overseas clinical trials for 5 innovative drug assets during the reporting period[71] - The company is actively pursuing partnerships and collaborations to enhance its research and development capabilities in oncology[60] Market Expansion and Strategy - Market expansion plans include entering three new countries by the end of the fiscal year[11] - The company is considering strategic acquisitions to bolster its market position, with a budget of $100 million allocated for this purpose[11] - The company is focusing on expanding its pipeline with multiple candidates targeting various conditions, including obesity and autoimmune diseases[33] - The company is actively pursuing regulatory approvals in the US and Europe for several of its drug candidates, indicating a strategic focus on international market expansion[64] - The company aims to leverage its innovative therapies to capture a larger share of the growing healthcare market in China[68] - The company has established a commercialization network covering over 25,000 hospitals and more than 200,000 offline retail pharmacies across over 30 provincial-level administrative regions in China[53] Corporate Governance - The board of directors is committed to high standards of corporate governance to protect shareholder interests and enhance corporate value[130] - The company has established four specialized committees to provide strategic guidance, including the Audit Committee and the Remuneration and Assessment Committee[130] - The board consists of 11 members, including 6 executive directors, 1 non-executive director, and 4 independent non-executive directors, ensuring a strong independent element for effective decision-making[134] - The company has mechanisms in place to ensure board independence, including the appointment and evaluation of independent non-executive directors[141] - The company has established a performance evaluation and assessment system linking management compensation to operational performance, with the remuneration and assessment committee responsible for setting and reviewing compensation policies[154] Employee Engagement and Diversity - The company aims to increase the proportion of female employees to 45% by 2030, with ongoing support for women's career development through initiatives like the Women's Leadership Program[183] - By 2025, the percentage of female employees, including senior management, is expected to reach 45.6%, reflecting a stable growth of 0.7% from the previous year[181] - The company has implemented a diversity policy that resulted in 13,800 employees participating in diversity training, accumulating 6,900 hours of training during the reporting period[179] - The proportion of minority employees reached 4% by 2025, while the percentage of foreign employees stood at 0.43%[181] Risk Management - The company has established a robust risk management system addressing potential risks across various business aspects, including R&D, clinical trials, production, procurement, sales, inventory management, financial reporting, and compliance[193] - The company’s compliance management framework includes a compliance committee led by directors and senior management, ensuring adherence to applicable policies and regulations[195] - The company regularly reviews its dividend policy and cannot guarantee the payment of dividends at any specific amount during any given period[188]